To include your compound in the COVID-19 Resource Center, submit it here.

OnCore performance

Ex-Pharmasset execs line up money, assets in OnCore to tackle HBV

After helping to develop blockbuster HCV drug Sovaldi sofosbuvir, a team of ex-Pharmasset Inc. executives now have lined up money and assets in OnCore Biopharma Inc.

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE